Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)

Active
Yes
Status
Posted
Published Date
October 10th, 2023
Close Date
October 13th, 2026
Award Ceiling
$150,000.00
Opportunity No.
PAR-24-047

Agency

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Summary

The National Institutes of Health (NIH) has posted a grant opportunity titled "Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)". This grant opportunity falls under the category of Health and is a discretionary grant. The grant does not require cost sharing or matching. The purpose of this grant is to accelerate the translation of NCI-supported methods/assays/technologies to the clinic, specifically focusing on the adaptation and clinical validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer control and prevention. The grant encourages multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. The grant does not support early-stage development of technology or the conduct of clinical trials, but rather the adaptation and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices. The grant has a closing date of October 13, 2026, and an award ceiling of $150,000. For more information and to apply, visit the following link: Additional Information. For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

Description

Through this Notice of Funding Opportunity (NOFO) is to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of this NOFO is on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" r "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer control and prevention. Research applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed for this NOFO encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.

Contact Information

Attachments
0 KB

Opportunity Lifecycle

Title
Type
Grant

Similar Opportunities

Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)". This grant aims to support extramural research in investigating and mitigating challenges faced in clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as liquid biopsies, or other biospecimens. The research funded under this grant will explore the preanalytical variability associated with the procurement and study of various biospecimens, such as small biopsies, blood, tissue swabs, tissue secretions, and bodily fluids. The goal is to improve the understanding of how different preanalytical conditions affect biomarkers and to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices. The grant does not require cost sharing or matching and falls under the category of health. The deadline for application submission is September 13, 2024. For more information and to apply, visit the following link: [Integrating Biospecimen Science Approaches into Clinical Assay Development Grant](http://grants.nih.gov/grants/guide/pa-files/PAR-22-049.html).
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)". This grant aims to accelerate the adoption and validation of molecular/cellular/imaging markers and assays for various purposes in cancer research, including detection, diagnosis, prognosis, monitoring, prediction of response or resistance to treatment, as well as markers for cancer prevention and control. The grant also supports the validation of pharmacodynamic markers and markers of toxicity. Applicants must have analytically validated assays for the intended clinical use of the markers and assays. The UH3 mechanism will provide support for the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. The grant can also be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests and investigate the performance and reproducibility of assays across multiple clinical laboratories are also encouraged. This funding opportunity requires multi-disciplinary collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. It is important to note that this grant is not intended for early-stage development of technology or the conduct of clinical trials, but rather for the validation of assays to the point where they could be integrated into clinical trials or studies as investigational assays. For more information and to apply for this grant, please visit the following link: [Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)](http://grants.nih.gov/grants/guide/pa-files/PAR-23-314.html).
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health is offering a federal grant opportunity titled "Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)". This grant aims to support the validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment. It also includes markers for cancer prevention and control. The grant will fund both analytical and clinical validation of assays to be used in cancer treatment, control, or prevention trials. The validation of pharmacodynamic markers and markers of toxicity is also supported. The grant requires multi-disciplinary collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. For more information and to apply, visit the following link: [Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)](http://grants.nih.gov/grants/guide/pa-files/PAR-23-313.html).
Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)". This grant aims to support the identification of small molecules that can be used as chemical probes or as agonists or antagonists of disease targets for therapy or immunotherapy. The grant will fund research in various stages of discovery, including assay development, high throughput screening, hit validation, and hit-to-lead optimization. The goal is to advance knowledge about disease targets and identify potential pre-therapeutic leads. The grant is open to various eligible applicants, including academic institutions, government agencies, and non-domestic entities. The deadline for application submission is September 7, 2026. For more information and to apply, visit the following link: [Assay development and screening grant](http://grants.nih.gov/grants/guide/pa-files/PAR-23-264.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.